Whole-body distribution and metabolism of [N-methyl-11C](R)-1-(2-chlorophenyl)-N-(1-methylpropyl)-3-isoquinolinecarboxamide in humans; an imaging agent for in vivo assessment of peripheral benzodiazepine receptor activity with positron emission tomography

Purpose11C-PK11195 is a radiopharmaceutical for in vivo assessment of peripheral benzodiazepine receptor (PBR) activity using PET. We sought to clarify the metabolic fate of 11C-PK11195 in a test–retest setting using radio-HPLC in comparison with radio-TLC, and the whole-body distribution in humans.Materials and methodsIn order to evaluate the reproducibility of radio-HPLC metabolite analyses, ten patients with Alzheimer’s disease (AD) underwent two successive 11C-PK11195 examinations on separate days. For comparison of different analytical methods, plasma samples from seven patients were also analysed by radio-TLC. In addition, we evaluated the whole-body distribution of 11C-PK11195 and its uptake in the brain.ResultsThe level of unmetabolized 11C-PK11195 decreased slowly from 96.3 ± 1.6% (mean±SD) at 5 min to 62.7 ± 8.3% at 40 min after injection. Large individual variation was observed in the amount of plasma 11C-PK11195 radiometabolites. The whole-body distribution of 11C-PK11195 showed the highest radioactivity levels in urinary bladder, adrenal gland, liver, salivary glands, heart, kidneys, and vertebral column. In addition, the hip bone and breast bone were clearly visualized by PET. In patients with AD, 11C-PK11195 uptake in the brain was the highest in the basal ganglia and thalamus, followed by the cortical grey matter regions and the cerebellum. Low 11C-PK11195 uptake was observed in the white matter.ConclusionOur results indicate that 11C-PK11195 is eliminated both through the renal and hepatobiliary systems. Careful analysis of plasma metabolites is required to determine the accurate arterial input function for quantitative PET measurement.

[1]  C Crouzel,et al.  Peripheral-type benzodiazepine receptors in the living heart characterized by positron emission tomography. , 1986, Circulation.

[2]  Lukasz Huminiecki,et al.  Congruence of tissue expression profiles from Gene Expression Atlas, SAGEmap and TissueInfo databases , 2003, BMC Genomics.

[3]  R B Banati,et al.  Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK11195 , 2000, Neurology.

[4]  Lars Farde,et al.  Measurement of Methylphenidate-Induced Change in Extrastriatal Dopamine Concentration using [11C]FLB 457 PET , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  Roger N Gunn,et al.  In-vivo measurement of activated microglia in dementia , 2001, The Lancet.

[6]  Alan C. Evans,et al.  PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis , 1997, Journal of neuroscience research.

[7]  B. Lecocq,et al.  PHARMACOKINETICS AND EFFECTS ON EXERCISE HEART RATE OF PK 11195 (52028 RP), AN ANTAGONIST OF PERIPHERAL BENZODIAZEPINE RECEPTORS, IN HEALTHY VOLUNTEERS , 1989, Fundamental & clinical pharmacology.

[8]  F. Turkheimer,et al.  Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study , 2004, Neurobiology of Disease.

[9]  D. Nutt,et al.  Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. , 2006, Trends in pharmacological sciences.

[10]  D. Nutt,et al.  Radioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites--current status. , 1993, Nuclear medicine and biology.

[11]  R. Butterworth,et al.  Peripheral benzodiazepine binding sites in Alzheimer's disease frontal and temporal cortex , 1991, Neurobiology of Aging.

[12]  G. L. Watkins,et al.  PET Imaging of human gliomas with ligands for the peripheral benzodiazepine binding site , 1989, Annals of neurology.

[13]  T G Turkington,et al.  Performance characteristics of a whole-body PET scanner. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  K. Krueger.  Molecular and functional properties of mitochondrial benzodiazepine receptors. , 1995, Biochimica et biophysica acta.

[15]  S. Galiègue,et al.  Peripheral benzodiazepine receptors and mitochondrial function , 2002, Neurochemistry International.

[16]  R B Banati,et al.  The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. , 2000, Brain : a journal of neurology.

[17]  E. Yoshikawa,et al.  Microglial activation and dopamine terminal loss in early Parkinson's disease , 2005, Annals of neurology.

[18]  Ronald Boellaard,et al.  Development of a Tracer Kinetic Plasma Input Model for (R)-[11C]PK11195 Brain Studies , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  D. R. Turton,et al.  An automated system based on solid phase extraction and HPLC for the routine determination in plasma of unchanged carbon-11 L-deprenyl Carbon-11 diprenorphine; carbon-11 flumazenil; Carbon-11 raclopride and Carbon-11 Scherring 23390 , 1993 .

[20]  J Versijpt,et al.  PET visualization of microglia in multiple sclerosis patients using [11C]PK11195 , 2003, European journal of neurology.

[21]  J. Sloan,et al.  Pharmacokinetics of the peripheral benzodiazepine receptor antagonist, PK 11195, in rats. The effect of dose and gender. , 2000, Pharmacological Research.

[22]  F. Campagne,et al.  TissueInfo: high-throughput identification of tissue expression profiles and specificity. , 2001, Nucleic acids research.

[23]  Gert Luurtsema,et al.  Optimizing an online SPE-HPLC method for analysis of (R)-[11C]1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide [(R)-[11C]PK11195] and its metabolites in humans. , 2005, Nuclear medicine and biology.